Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Recent & Breaking News (NEO:CYBN)

Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy

Business Wire April 12, 2023

Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Business Wire March 8, 2023

Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

Business Wire March 2, 2023

Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

Business Wire February 28, 2023

Cybin Announces Streamlined Clinical Alignment

Business Wire February 22, 2023

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

Business Wire February 14, 2023

Cybin (NEO:CYBN) announces first-in-human dosing of its DMT molecule

Trevor Abes  February 1, 2023

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Business Wire February 1, 2023

Cybin to Host Virtual R&D Day on February 28, 2023

Business Wire January 26, 2023

Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Business Wire January 18, 2023

Trippy Trading: Top Psychedelic Stocks For 2023

TheNewsWire January 17, 2023

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Business Wire January 12, 2023

Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs

Business Wire January 8, 2023

Cybin Highlights 2022 Accomplishments and Milestones

Business Wire December 20, 2022

Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting

Business Wire December 6, 2022

Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

Business Wire November 15, 2022

Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

Business Wire November 14, 2022

Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

Business Wire November 10, 2022

Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

Business Wire November 3, 2022

Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit

Business Wire November 1, 2022